|
| |
Celera GenomicsCelera is engaged principally in integrating high throughput technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of genomic and related biological and medical information. Pharmaceutical, biotechnology, and academic customers use this information, along with customized information technology solutions provided by Celera, to enhance their capabilities in the fields of life science research and pharmaceutical and diagnostic discovery and development. Celera recently expanded its focus to include therapeutic discovery and development. Celera intends to leverage its capabilities in genomics, proteomics, and bioinformatics, both in internal programs and through collaborations, to identify drug targets and diagnostic markers, and to discover and develop novel therapeutic candidates. Initially, Celera intends to focus its therapeutic discovery efforts in the field of oncology. In June 2001, Celera announced the signing of a definitive merger agreement with Axys, a small molecule drug discovery and development company. Celera believes that Axys’ medicinal and structural chemistry and biology capabilities will accelerate the development of its therapeutic discovery business. Celera is also participating in the commercialization of diagnostic products based on its discoveries through Celera Diagnostics, a recently announced joint venture with Applied Biosystems.
| Contact Details: |
| 45 West Gude Drive |
| Rockville |
| MD |
| 20850 |
| United States of America |
| Tel: | +1 240 453 3000 |
| Fax: | +1 240 453 4000 |
| Email: | robert.bennett@celera.com |
| WWW: | www.celera.com/
|
|
Loading...
|
Recent Publications by Celera Genomics: |  |
Finding homologs in amino acid sequences using network BLAST searches.
A method for the quantitation of mirfentanil hydrochloride (A-3508.HCl) in... | 9th May, 2009
| Celera Genomics, Foster City, California, USA.
| Curr Protoc Bioinformatics. 2009 Mar;Chapter 3:Unit 3.4.
DOI Direct Link |
Finding homologs to nucleotide sequences using network BLAST searches.
Basic Local Alignment Search Tool (BLAST) can identify possible homologs... | 18th October, 2008
| Celera Genomics, Foster City, California, USA.
| Curr Protoc Bioinformatics. 2002 Aug;Chapter 3:Unit 3.3.
DOI Direct Link |
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
BLAST, Basic Local Alignment Search Tool is used more frequently than any... | 17th July, 2008
| Department of Medicinal Chemistry, Celera Genomics, 180 Kimball Way, South
| ChemMedChem. 2007 Jan;2(1):58-61.
DOI Direct Link |
Finding homologs in amino acid sequences using network BLAST searches.
BLAST, Basic Local Alignment Search Tool is used more frequently than any... | 15th May, 2008
| Celera Genomics, Foster City, California and Research Group for
| Curr Protoc Bioinformatics. 2003 Feb;Chapter 3:Unit 3.4.
DOI Direct Link |
Systematic identification of pseudogenes through whole genome expression evidence profiling.
The identification of pseudogenes is an integral and significant part of... | 31st October, 2006
| Celera Genomics, 45 West Gude Dr, Rockville, MD 20850, USA.
| Nucleic Acids Res. 2006;34(16):4477-85. Epub 2006 Aug 31.
DOI Direct Link |
→View more Celera Genomics research publications. |
Press Releases on Celera Genomics:
|
 |
| Moores UCSD Cancer Center Luau and Longboard Invitational Announce Dr. David Easter to Receive the 2009 Rell Sunn 'Queen of Makaha' Award |
19th June, 2009 |
The Moores UCSD Cancer Center Luau & Longboard Invitational |
Brilliant Doctor Brings the 'Aloha Spirit' into a Patient-Centered Approach to Surgical Medicine and Training
SAN DIEGO, June 19 /PRNewswire/ -- The Moores UCSD Cancer Center Luau &
|
| DiagnoCure announces second quarter financial results |
8th June, 2009 |
DiagnoCure Inc. |
Ticker Symbol: CUR
Gen-Probe to initiate FDA pivotal clinical study for the PCA3 prostate
cancer test
QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company
|
| Accuri Cytometers Completes $13 Million Series C Financing |
8th July, 2008 |
Accuri Cytometers Inc. |
ANN ARBOR, Mich., July 8 /PRNewswire/ -- Accuri Cytometers Inc., a life
sciences company developing revolutionary bench-top flow cytometer systems,
today announced the completion of a $13 million
|
| BioSeeker launches new report "The Global Structure of Prostate
|
1st January, 1970 |
Bioseeker |
BioSeeker launches new report "The Global Structure of Prostate Cancer R&D"
In Europe and the US there are close to 20
million
|
| Milestone in the development of Histone Deacetylase Inhibitors |
1st January, 1970 |
Leaddiscovery |
Milestone in the development of Histone
Deacetylase Inhibitors
The field of histone
deacetylase (HDACs) inhibition has recently started to move from a preclinical
approach to one actively
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 22 individuals from Celera Genomics using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1544 times since April 2007, the link to the organisation's website has been followed 193 times Recent Search Terms used to find this page: celera genomics | celera | perkin elmer celera genomics group quote | celera genomics | celera genomics | celera | Celera Genomics | celera genomics | celera genomics | CurGen cancer | . Search for more companies in Rockville Search for more companies in MD This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Celera Genomics |
